KLDO News and Press, Kaleido Biosciences Inc. From 03/24/21

KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal registration program Company to host conference call today at 8:30am ET ...

Today, we take our first in-depth look at Kaleido Biosciences, which is using the microbiome to target several indications. The company also has seen encouraging results from its COVID-19 efforts and recently addressed near term funding concerns. A full investment analysis follows...

Kaleido Biosciences (KLDO): Q4 GAAP EPS of -$0.56 beats by $0.11.Revenue of $0.24MCash and cash equivalents of $46.2MPress Release For further details see: Kaleido Biosciences EPS beats by $0.11

Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021 KB295 study in patients with ulcerative colitis remains on track with topline data anticipated mid-year 2021 LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq...

Latest Sec Form 4 filings indicate that Kaleido Biosciences (KLDO) Daniel Menichella has purchased 20K of common shares at $11.50 apiece to initiate a position in the company.Early February, the company announced an underwritten public offering of $50M worth common stock to fund its...

LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Dan Menichella, Pre...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire CAMBRIDGE, Mass. , Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life science...

Kaleido Biosciences ([[KLDO]] +13.4%) announces that, in connection with its recent public offering, the underwriters have fully exercised their option to purchase an additional 787.5K shares.The exercise of the option increases the size of the offering to an aggregate of 6M shares at a price...

LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that, in connection with ...

Kaleido Biosciences (KLDO) announced that it intends to sell $50M of shares in an underwritten public offering.The company also intends to grant the underwriters a 30-day option to purchase an additional $7.5M of shares.Kaleido plans to use proceeds from the offering to fund its continue...